Mostrando 10 resultados de: 19
Filtros aplicados
Publisher
Pharmacogenomics(3)
Pharmacogenomics Journal(2)
Advances in Biological Psychiatry(1)
BMC Psychiatry(1)
Behaviour Research and Therapy(1)
Área temáticas
Enfermedades(18)
Farmacología y terapéutica(6)
Psicología diferencial y del desarrollo(4)
Bioquímica(2)
Fisiología humana(2)
Origen
scopus(19)
Cognitive behaviour therapy response and dropout rate across purging and nonpurging bulimia nervosa and binge eating disorder: DSM-5 implications
ArticleAbstract: Background: With the imminent publication of the new edition of the Diagnostic and Statistical ManuaPalabras claves:Binge eating disorder (BED), Bulimia nervosa (BN), classification, Cognitive-behavioural therapy (CBT), DSM-5Autores:Agüera Z., Arcelus J., Fernández‐aranda F., Islam M.A., Menchón J.M., Murcia S.J., Penãs-Lledó E.M., Riesco N., Roser Granero, Sánchez‐díaz I., Vicente E.Fuentes:scopusAssociation between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
ArticleAbstract: Background: An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has bPalabras claves:A-1438G polymorphism, Risperidone, Schizophrenia, Seretonin 2A receptor, T102C polymorphismAutores:Adrián LLerena, Cáceres M.C., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusABCB1 gene polymorphisms and violent suicide attempt among survivors
ArticleAbstract: Introduction: Those suicide attempters that choose violent methods dramatically diminish the possibiPalabras claves:ABCB1, Suicide attempt, Violent suicide methodsAutores:Adrián LLerena, Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 polymorphism in patients with eating disorders
ArticleAbstract: CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is,Palabras claves:CYP2D6, Eating disorders, pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Agüera Z., Dorado P., Estivill X., Fernández‐aranda F., Gratacòs M., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 variation, behaviour and psychopathology: Implications for pharmacogenomics-guided clinical trials
ArticleAbstract: Individual and population differences in polymorphic cytochrome P450 enzyme function have been knownPalabras claves:clinical trials, CYP2D6, endogenous compound metabolism, personality traits, pharmacogenetics, psychopathologyAutores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusElevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment
ArticleAbstract: The polymorphic CYP2C19 enzyme metabolizes psychoactive compounds and is expressed in the adult livePalabras claves:Autores:Adrián LLerena, Baune B.T., Binder E.B., Carrillo-Roa T., Courtet P., Dannlowski U., de Quervain D.J., Ingelman-Sundberg M., Jukić M.M., Miksys S., Novalen M., Opel N., Papassotiropoulos A., Penãs-Lledó E.M., Renblom A., Sim S.C., Ström J., Tyndale R.F.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusNo effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients [2]
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopus